Transient Receptor Potential Melastatin 8 Channels: An Important Diagnostic Biomarker for Gastric Cancer Patients
Transient Receptor Potential Melastatin 8 Channels: An Important Diagnostic Biomarker for Gastric Cancer Patients
Yasaman Golab Iranshahi,1Issa Layali,2Pezhman Shafiei Asheghabadi,3,*
1. 1 Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. 2 Biology Association, Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. 2. 1Department of Biochemistry and Biophysics, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. 2 Biology Association, Young Researchers and Elite Club, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. 3. 1Department of Cellular and Molecular Biology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. 2Farhikhtegan Medical Convergence Sciences Research Center, Farhikhtegan Hospital, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
Introduction: Gastric cancer (GC) is the 4th deadliest cancer in the world and patients have a poor prognosis. Also, it is a multifactorial disease, and genetic and epigenetic factors are involved in its occurrence. Due to the lack of specific biomarkers, most patients do not have obvious symptoms in the early stages, so paying attention to early diagnostic approaches is very important. In this study, we describe the role of transient receptor potential melastatin 8 channels (TRPM8) in early detection of GC.
Methods: In order to obtain the latest developments in this field, it was conducted an extensive search in PubMed and Google Scholar databases from 2020-2024 and identified 27 articles that were most relevant to our topic.
Results: In recent years, Non-Coding RNAs (ncRNAs) has emerged as a drug target in the treatment of cancer, especially in the fields of immunity, cancer metabolism and metastasis, and powerful diagnostic biomarkers. These biomarkers provide the possibility of accurately predicting treatment response and prognosis in most cancer patients, as well as creating a personalized treatment strategy for each person. For example, MicroRNAs (miRNAs) have been identified to regulate the expression of target Messenger RNAs (mRNAs) and thereby modify the vital biological mechanisms of cancer. These ncRNAs, which are usually abnormally expressed in cancerous tissues, play a key role in carcinogenesis, and their evaluation has potential benefits in the diagnosis, prognosis, or treatment of cancer. But for GC, there are mainly no specific biomarkers. In a 2023 research, TRPM8 were identified as a novel diagnostic biomarker for GC, and tumor tissues showed significantly higher expression levels of TRPM8 compared to normal gastric tissue Showed. This study shows the essential role of TRPM8 in cell proliferation and suggests that TRPM8 may be used as a potential therapeutic target for GC patients.
Conclusion: Due to the lack of specific biomarkers, most GC patients are diagnosed in advanced stages. Recently, TRPM8 has been identified as a diagnostic biomarker that has a high expression level in gastric tumor tissues, which is promising for the emergence of early detection approaches and molecular targeted therapies for GC.